The expression of the GSE22255 DataSet full SOFT file is available at <https://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS4521>).

1.Introduction {#sec005}
==============

Stroke is the leading cause of disability and the second leading cause of death worldwide, with an annual incidence of approximately 17 million. It is estimated that every 40 seconds, there is a stroke in the United States, 87% of which are ischemic strokes \[[@pone.0227481.ref001]\]. Currently, urgent-in-time thrombosis treatment is an effective therapeutic strategy and requires long-term antiplanet or anticoagulant medication to prevent IS recurrence \[[@pone.0227481.ref002]\].

Sex differences were seen for IS as females had higher incidence and longer life expectancy but worse functional outcomes \[[@pone.0227481.ref003],[@pone.0227481.ref004]\], which might be due to different risk factors \[[@pone.0227481.ref005],[@pone.0227481.ref006],[@pone.0227481.ref007]\], anatomic structural Willis incompletion or white integrity \[[@pone.0227481.ref008],[@pone.0227481.ref009]\], biologically inherent sex chromosome complemented with gonadal hormones \[[@pone.0227481.ref010],[@pone.0227481.ref011],[@pone.0227481.ref012]\], socialized reasons of in-hospital care \[[@pone.0227481.ref006],[@pone.0227481.ref013]\], and therefore, pathology and treatment \[[@pone.0227481.ref014],[@pone.0227481.ref015]\]. However, animal-based research has observed decreased infarct size and improved outcomes in female compared to males \[[@pone.0227481.ref016]\]. Otherwise, a parallel characterization of the cytokine and chemokine response to stroke in the human and mouse brain at different stages of infarct resolution have been reported \[[@pone.0227481.ref017]\]. Many studies have observed sex differences in IS; however, the mechanism has yet to be elucidated.

High-throughput platforms for analysis of gene expression, such as microarrays, are promising tools for inferring biological relevancy, especially the complex network during the process of IS. However, there is no genome-wide exploration of the sex-specific mechanism in IS. In this study, we investigated the well-documented original data from the Gene Expression Omnibus (GEO) \[[@pone.0227481.ref018]\]. The human stroke blood sample dataset, GSE22255, was selected for further exploration \[[@pone.0227481.ref019]\]. Gene ontology and biological function annotation were performed followed by PPI network and related analysis. By using the bioinformatic method, new insight into the mechanisms of IS can be obtained which may reveal potential biomarker candidates for clinical use and drug target discovery.

2. Materials and methods {#sec006}
========================

2.1. Microarray data {#sec007}
--------------------

The authors declare that all supporting data are available within the article \[and its online supplementary files\]. The GEO dataset mining results showed that few homogeneous studies available ([S1 Fig](#pone.0227481.s001){ref-type="supplementary-material"}). So, for the study object of translation of clinical practice, we chose human whole blood cell datasets for this comparative bioinformatic analysis work. The gene expression profiles of GSE22255 as whole blood cell datasets for human cerebral ischemia were downloaded from the GEO \[[@pone.0227481.ref020]\]. GSE22255 was performed on GPL570, \[HG-U133 Plus 2\] Aymetrix Human Genome U133 Plus2.0 Array. The GSE22255 data set contained 40 samples, including 10 female IS patients, 10 male IS patients, 10 female controls, and 10 male controls \[[@pone.0227481.ref019]\]. The imported CEL files were subjected to background correction, normalization, and summarization using the robust multichip average (RMA) algorithm for normalization \[[@pone.0227481.ref019]\]. The GSE22255 study was approved by the ethics committees of the participating institutions. All participants were informed of the study and provided informed consent \[[@pone.0227481.ref019]\]. For the analysis of this study, no ethics approval and patients' informed consent was needed.

2.2. Identification of DEGs {#sec008}
---------------------------

The analysis was carried out by open source software which significantly simplified the development and distribution of preprocessing methods for gene expression microarrays with BioConductor R and package (<https://www.r-project.org/>) \[[@pone.0227481.ref021],[@pone.0227481.ref022]\]. The expression of the GSE22255 DataSet full SOFT file was downloaded (<https://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS4521>). Female and male IS patients and controls were assigned according to the annotation of the GSE22255. DEGs were identified after probe signal average and normalized, where the log~2~ of a total of 54,665 genes were calculated. The genes with LogFC\>1 and a *P*-value \<0.05 were considered differentially expressed. Sex-specific DEGs were obtained by comparison of female IS patients with female controls, and male IS patients with male controls, respectively.

2.3. Bioinformatic analysis {#sec009}
---------------------------

### 2.3.1 Gene ontology and pathway enrichment analysis of DEGs {#sec010}

Gene Ontology (GO) \[[@pone.0227481.ref023]\] cellular component, molecular function, biological process and KEGG pathway enrichment were analysed using a web-based tool, Search Tool for the Retrieval of Interacting Genes (STRING) (version 10.5) (<https://string-db.org/>) \[[@pone.0227481.ref024]\]. Enrichment tests were based on the hypergeometric distribution \[[@pone.0227481.ref025]\]. False discovery rate was used to evaluate significance \[[@pone.0227481.ref026]\].

### 2.3.2 Integration of Protein-Protein Interaction (PPI) network analysis {#sec011}

STRING was used to evaluate the interactive (PPI) relationships between DEGs. Evidence-based interactions including text mining, experimental and database interactions achieving combined score \>0.4 were selected as significant\[[@pone.0227481.ref024]\]. PPI networks were constructed using the Cytoscape software \[[@pone.0227481.ref027]\].

A Cytoscape plug-in, MCODE \[[@pone.0227481.ref028]\], was used to screen the modules of PPI network identified. Modules inferred using the default settings with degree cutoff at 2, node score cutoff at 0.2, *K* core at 2, and a maximum depth of 100.

A Cytoscape plug-in, CytoNCA \[[@pone.0227481.ref029]\], which integrated calculation, evaluation, and visualization analysis for multiple centrality, was proposed to screen essential DEGs. PPI network topological structure and relationship characteristics including: Betweenness Centrality (BC), Closeness Centrality (CC), Degree Centrality (DC), Eigenvector Centrality (EC), Local Average Connectivity-based Centrality (LAC), Network Centrality (NC), Subgraph Centrality (SC), and Information Centrality (IC) were calculated. The appropriate minimum threshold varied and was determined by the network nodes and edges distributions. Top 10 essential DEGs were screened.

### 2.3.3 Pathways enrichment and interrelation analysis {#sec012}

KEGG pathways enrichment and interrelation Analysis. Pathway enrichment analysis was carried out using DAVID(The Database for Annotation, Visualization and Integrated Discovery) databse\[[@pone.0227481.ref030]\]. Group *P-*values \<0.01, minimum gene in clusters was set at 4. Enriched KEGG pathway and overlapped DEGs interrelation analysis for female and male IS patients was conducted and the interrelation network was reconstructed in Cytoscape software.

3. Results {#sec013}
==========

The bioinformatic analysis results were following the route showed in [S2 Fig](#pone.0227481.s002){ref-type="supplementary-material"}.

3.1. Identification of DEGs {#sec014}
---------------------------

The GSE22255 data set contained 40 peripheral blood samples, including 10 female IS patients, 10 male IS patients, 10 female controls, and 10 male controls. IS patients were required to have suffered only one stroke episode, at least 6 months before the blood collection, and controls could not have a family history of stroke. Participants with severe anemia or active allergies were also excluded \[[@pone.0227481.ref019]\]. Sex-specific DEGs were obtained by comparison of female IS patients with female controls, and male IS patients with male controls, respectively. All sex-specific DEGs are presented in [Fig 1](#pone.0227481.g001){ref-type="fig"}. In the female dataset, 185 (73 upregulated and 112 downregulated) DEGs were obtained, while 461 DEGs (297 upregulated and 164 downregulated), within which 118 DEGs overlapped (7 similar changes and 111 opposite changes in female and male), were obtained in the male dataset.

![Sex-specific DEGs in IS.](pone.0227481.g001){#pone.0227481.g001}

3.2. Bioinformatic analysis {#sec015}
---------------------------

For the 185 female-specific DEGs, 461 male-specific DEGs, 118 overlapping DEGs, functional annotation was carried out. However, only part of the collection obtained functional annotations. The functionally annotated DEGs including 126 (68.1%) female-specific, 250 (54.2%) male-specific, and 75 (63.6%) overlapping DEGs were put for further GO, KEGG and PPI analysis.

### 3.2.1 GO and pathway enrichment analysis {#sec016}

Top 5 or less enrichment analyses results were shown for each part of the GO analysis. The cellular component, molecular function and biological process enrichment analyses results are shown in [Table 1](#pone.0227481.t001){ref-type="table"}. Female, male and overlapping DEGs significantly took part in similar and overlapping cellular components, molecular functions and KEGG pathways, but divergent biological processes. For cellular component analysis, female, male and overlapping DEGs mainly enriched in the extracellular space (GO.0005615). For molecular function, female, male and overlapping DEGs mainly enriched in chemokine receptor binding (GO.0042379) and cytokine activity (GO.0005125). For GO biological process enrichment analysis, male-specific DEGs took part in regulation of apoptotic processes (GO.0042981), regulation of cell death (GO.0010941), positive regulation of cell death (GO.0010942), and positive regulation of programmed cell death (GO.0043068).

10.1371/journal.pone.0227481.t001

###### GO enrichment analysis in networks.

![](pone.0227481.t001){#pone.0227481.t001g}

  GO        gender       pathway ID                                                                                                 pathway description          observed gene count   false discovery rate
  --------- ------------ ---------------------------------------------------------------------------------------------------------- ---------------------------- --------------------- ----------------------
  CC        female       GO.0005615                                                                                                 extracellular space          34                    4.10E-11
            GO.0005833   haemoglobin complex                                                                                        4                            0.000138              
            GO.0044421   extracellular region part                                                                                  42                           0.00292               
  　        GO.0030141   secretory granule                                                                                          10                           0.00505               
  male      GO.0005615   extracellular space                                                                                        35                           0.00229               
  overlap   GO.0005615   extracellular space                                                                                        17                           0.00223               
            GO.0009897   external side of plasma membrane                                                                           7                            0.0132                
  　        GO.0098552   side of membrane                                                                                           8                            0.0484                
  MF        female       GO.0042379                                                                                                 chemokine receptor binding   10                    1.88E-09
            GO.0005125   cytokine activity                                                                                          13                           1.39E-08              
            GO.0005126   cytokine receptor binding                                                                                  14                           4.65E-08              
            GO.0008009   chemokine activity                                                                                         8                            2.06E-07              
  　        GO.0045236   CXCR chemokine receptor binding                                                                            6                            3.03E-07              
  male      GO.0005126   cytokine receptor binding                                                                                  20                           3.86E-09              
            GO.0005125   cytokine activity                                                                                          15                           7.71E-07              
            GO.0042379   chemokine receptor binding                                                                                 9                            1.17E-05              
            GO.0005102   receptor binding                                                                                           34                           0.000166              
  　        GO.0000982   transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding   17                           0.000243              
  overlap   GO.0005125   cytokine activity                                                                                          10                           5.22E-07              
            GO.0005126   cytokine receptor binding                                                                                  11                           5.22E-07              
            GO.0042379   chemokine receptor binding                                                                                 7                            8.87E-07              
            GO.0008009   chemokine activity                                                                                         5                            0.000549              
  　        GO.0005102   receptor binding                                                                                           16                           0.000865              
  BP        female       GO.0009617                                                                                                 response to bacterium        25                    1.85E-13
            GO.0051707   response to other organisms                                                                                27                           4.89E-12              
            GO.0032496   response to lipopolysaccharide                                                                             19                           8.24E-12              
            GO.0006955   immune response                                                                                            35                           1.12E-11              
  　        GO.0033993   response to lipid                                                                                          27                           7.12E-11              
  male      GO.0042981   regulation of apoptotic process                                                                            59                           1.45E-15              
            GO.0010941   regulation of cell death                                                                                   59                           1.19E-14              
            GO.0002237   response to molecule of bacterial origin                                                                   28                           1.53E-14              
            GO.0010942   positive regulation of cell death                                                                          37                           5.69E-14              
  　        GO.0043068   positive regulation of programmed cell death                                                               36                           5.69E-14              
  overlap   GO.0006954   inflammatory response                                                                                      16                           1.80E-08              
            GO.0002684   positive regulation of immune system process                                                               20                           2.03E-08              
            GO.0032496   response to lipopolysaccharide                                                                             13                           3.93E-08              
            GO.0033993   response to lipid                                                                                          19                           3.93E-08              
  　        GO.0060326   cell chemotaxis                                                                                            11                           3.93E-08              

CC: cellular component; MF: molecular function; BP: biological process

### 3.2.2. PPI network and module screening {#sec017}

Based on the information in the STRING database, female- ([Fig 2A](#pone.0227481.g002){ref-type="fig"}), male-specific ([Fig 3A](#pone.0227481.g003){ref-type="fig"}) and overlapping ([Fig 4A](#pone.0227481.g004){ref-type="fig"}) DEGs were put into PPI networks. The PPI networks were analyzed using the Cytoscape plug-in, MCODE. Significant modules were clustered ([Fig 2B](#pone.0227481.g002){ref-type="fig"}, [Fig 3B](#pone.0227481.g003){ref-type="fig"}, [Fig 4B](#pone.0227481.g004){ref-type="fig"}, [Table 2](#pone.0227481.t002){ref-type="table"}). The topologically essential DEGs screened by CytoNCA were outlined by thicker border circles ([Fig 2A](#pone.0227481.g002){ref-type="fig"}, [Fig 3A](#pone.0227481.g003){ref-type="fig"}, [Fig 4A](#pone.0227481.g004){ref-type="fig"}). The top 10 significant fold change in overlapping DEGs were shown in parallel with PPI ([Fig 2C](#pone.0227481.g002){ref-type="fig"}, [Fig 3C](#pone.0227481.g003){ref-type="fig"}, [Fig 4C](#pone.0227481.g004){ref-type="fig"}).

![Female-specific PPI networks in IS.\
A. Pink circles represent upregulated DEGs, blue circles represent downregulated DEGs, thicker red border emphasizes CytoNCA topologically significant DEGs. B. MCODE cluster of PPI networks. C. Top 10 CytoNCA significant DEGs. The isolated DEGs indicated no experimentally validated or predicted protein-protein interactions.](pone.0227481.g002){#pone.0227481.g002}

![Male-specific PPI network sin IS.\
Yellow circles represent upregulated DEGs, green circles represent downregulated DEGs, thicker red border emphasizes CytoNCA topologically significant DEGs. B. MCODE cluster of PPI networks. C. Top 10 CytoNCA significant DEGs. The isolated DEGs indicated no experimentally validated or predicted protein-protein interactions.](pone.0227481.g003){#pone.0227481.g003}

![Female and male overlapping PPI networks in IS.\
A. Coregulated DEGs were shown in a tow color circle. Pink represents upregulated DEGs in females, blue represents downregulated DEGs in females, yellow stands upregulated DEGs in males, green represents downregulated DEGs in males; thicker red border emphasizes CytoNCA topologically significant DEGs. B. MCODE cluster of PPI networks. C. Top 10 CytoNCA significant DEGs.](pone.0227481.g004){#pone.0227481.g004}

10.1371/journal.pone.0227481.t002

###### MCODE modules from PPI networks.

![](pone.0227481.t002){#pone.0227481.t002g}

  description   MCODE score   Nodes   
  ------------- ------------- ------- -----------------------------------------------------------------------------
  female        cluster1      11      GPR18 PF4 CCL4 CCR2 CCL20 ICAM1 P2RY13 CXCL1 CXCL2 CXCL5 CXCL3 P2RY13 HCAR3
                cluster2      4.8     IL6 IFNG FOS PTGS2 IL1A IL1B
  male          cluster1      11      P2RY13 CCR3 CXCL1 HCAR3 CCR2 IL8 CXCL3 CXCR4 CXCL2 P2RY12 CCL20
  　            cluster2      6.286   ICAM1 JUN CCL2 TNF IL1B IFNG IL6 PTGS2
  overlap       cluster1      7       P2RY13 CCL20 CXCL1 HCAR3 CXCL2 P2RY12 CXCL

### 3.2.3. KEGG pathway enrichment and interrelation analysis {#sec018}

For the female- and male-specific DEGs that presented opposite modulatory mechanisms in overlapping DEGs, the pathway interrelations were used to investigate the bi-modulatory (female-down-male-up) DEGs as shown in [Table 3](#pone.0227481.t003){ref-type="table"}. These genes are mainly involved in pathways including NOD-like receptor signalling pathways, cytokine-cytokine receptor interactions, TNF-signalling pathway, Rheumatoid arthritis, and NF-kappa B-signalling pathway etc ([Fig 5](#pone.0227481.g005){ref-type="fig"}). The detailed interactions were included in the [S3 Fig](#pone.0227481.s003){ref-type="supplementary-material"}\_html. Interleukin-1B (IL1B) and Interleukin-6 (IL6) took part in pathways which are the NOD-like receptor signalling pathways, cytokine-cytokine receptor interactions, TNF-signalling pathway, and Rheumatoid arthritis pathways; C-X-C motif chemokine ligands (CXCL) 1, 2, and 3 took part in 2--3 pathways including the TNF-signalling pathway, cytokine-cytokine receptor interactions and NOD-like receptor signalling pathways etc.

![KEGG pathways enrichment and interrelation analysis.\
Coregulated DEGs were shown in a tow color circle. Pink represents upregulated DEGs in females, blue represents downregulated DEGs in females, yellow stands upregulated DEGs in males, green represents downregulated DEGs in males; pink rectangles represent enriched KEGG pathways. The protein-protein interactions were not included in the pathway and DEG interrelations.](pone.0227481.g005){#pone.0227481.g005}

10.1371/journal.pone.0227481.t003

###### Interrelation between overlapping DEGs and enriched KEGG pathways.

![](pone.0227481.t003){#pone.0227481.t003g}

  Pathway                                  gene count   p value    genes
  ---------------------------------------- ------------ ---------- ------------------------------------------------------------
  Salmonella infection                     9            5.80E-09   CCL4,CXCL1,CXCL2,CXCL3,NLRC4,IFNG,IL1A,IL1B,IL6
  Cytokine-cytokine receptor interaction   11           2.10E-07   CCL20,CCL4,CCR2,CXCL1,CXCL2,CXCL3,IFNB1,IFNG,IL1A,IL1B,IL6
  TNF signaling pathway                    8            8.50E-07   CCL20,CXCL1,CXCL2,CXCL3,ICAM1,IL1B,IL6,PTGS2
  Legionellosis                            6            6.70E-06   CXCL1,CXCL2,CXCL3,NLRC4,IL1B,IL6
  NOD-like receptor signaling pathway      6            8.00E-06   CXCL1,CXCL2,NLRC4,NLRP3,IL1B,IL6,
  Rheumatoid arthritis                     6            7.30E-05   CCL20,ICAM1,IFNG,IL1A,IL1B,IL6,
  Influenza A                              7            2.10E-04   NLRP3,ICAM1,IFNB1,IFNG,IL1A,IL1B,IL6
  African trypanosomiasis                  4            5.90E-04   ICAM1,IFNG,IL1B,IL6
  Graft-versus-host disease                4            5.90E-04   IFNG,IL1A,IL1B,IL6
  Malaria                                  4            1.90E-03   ICAM1,IFNG,IL1B,IL6
  Chemokine signaling pathway              6            2.30E-03   CCL20,CCL4,CCR2,CXCL1,CXCL2,CXCL3
  Cytosolic DNA-sensing pathway            4            4.10E-03   CCL4,IFNB1,IL1B,IL6
  Inflammatory bowel disease (IBD)         4            4.10E-03   IFNG,IL1A,IL1B,IL6
  Measles                                  5            4.40E-03   ICAM1,IFNG,IL1B,IL6
  Leishmaniasis                            4            5.40E-03   CXCL1,CXCL2,CXCL3,NLRC4,IL1B,IL6
  Pertussis                                4            6.30E-03   NLRP3,IL1A,IL1B,IL6
  NF-kappa B signaling pathway             4            9.60E-03   CCL4,ICAM1,IL1B,PTGS2,

4. Discussion {#sec019}
=============

Genome-wide analysis (GWAS) has exposed significant aspects of ischemic stroke \[[@pone.0227481.ref031]\]. Some important SNP polymorphisms were discovered associated with IS including 5 C-reactive protein (CRP) SNPs \[[@pone.0227481.ref032]\], or (rs9943582, -154G/A) in the 5\' flanking region of (APLNR) was shown to be significantly associated with stroke in the Japanese population. In the previous study, 16 genes including TTC7B significantly changed in the IS group compared with age- and gender-matched controls \[[@pone.0227481.ref019]\]. On the hypothesis that female and male IS had different mechanisms, female and male IS were compared to healthy controls. As the results showed, 185 (73 upregulated and 112 downregulated) DEGs were obtained in the female dataset, 461 DEGs (297 upregulated and 164 downregulated) in the male dataset. In sex-specific DEGs, there were a group of overlapping DEGs but with opposite changes, which lead to a comparatively smaller amount of DEGs in the overall group. The IS blood sample also presented a smaller amount of DEGs compared with early or advanced atherosclerotic plaque samples \[[@pone.0227481.ref033]\]. The probable reason is that IS is a less stable pathological state and lacks biological markers compared with atherosclerotic plaque. Males double the DEGs and a larger portion of upregulated DEGs than females in this study, which indicated an underlying recovery mechanism for male IS protection and better outcomes than females \[[@pone.0227481.ref003]\]. After the identification of sex-specific DEGs in IS, the DEGs were put into multi-step bioinformatic functional annotations. The functionally annotated DEGs including 126 (68.1%) female-specific, 250 (54.2%) male-specific, and 75 (63.6%) overlapping DEGs were put for further GO, KEGG and PPI analysis. Although the functional annotation category did not cover all the DEGs, this information could still provide a whole overview and therapeutic drug strategy for sex-specific and opposite modulatory mechanisms in IS patients.

The cross-talks between the vascular and immune system play a critical role in both female and male strokes. Female, male, and overlapping DEGs enriched in the functional categories of chemokine receptor binding (GO.0042379) and cytokine activity (GO.0005125) ([Table 1](#pone.0227481.t001){ref-type="table"}). In this study, IL6 not only obtained key centrality but also gained high centrality in female, male and overlapping PPI networks (Figs [2](#pone.0227481.g002){ref-type="fig"}, [3](#pone.0227481.g003){ref-type="fig"} and [4](#pone.0227481.g004){ref-type="fig"}). KEGG pathway enrichment and interrelation analysis of female and male overlapping DEGs showed the involved interrelation between the pathways and bi-modulatory (female-down-male-up) DEGs ([Table 3](#pone.0227481.t003){ref-type="table"}, [Fig 5](#pone.0227481.g005){ref-type="fig"}). These genes were mainly involved in pathways including NOD-like receptor signalling pathways, cytokine-cytokine receptor interactions, TNF-signalling pathway, Rheumatoid arthritis, and the NF-kappa B-signalling pathway. IL1B took part in 5 pathways, and IL6 took part in 4 pathways which are NOD-like receptor signalling pathways, cytokine-cytokine receptor interactions, TNF-signalling pathway, and Rheumatoid arthritis pathways; CXCL1, CXCL2, and CXCL3 took part in 2--3 pathways including the TNF-signalling pathway, cytokine-cytokine receptor interactions, and NOD-like receptor signalling pathways. Several studies have shown that immune responses including IL6 \[[@pone.0227481.ref034]\], IgA\[[@pone.0227481.ref035]\], CXCL16 \[[@pone.0227481.ref036]\], TNFSF4\[[@pone.0227481.ref037]\], and IL10 \[[@pone.0227481.ref038]\] were involved in stroke. IL6 and infarction size were reported as independent predictors of short-term stroke outcome in young Egyptian adults \[[@pone.0227481.ref034]\]. For the opposite changes of these DEGs, females presented downregulated tendencies for these inflammatory and immune process-related pathways, while males presented the opposite ([Fig 3](#pone.0227481.g003){ref-type="fig"}). The divergent immunological alterations were also observed in mice MCAO explorations, where males had a greater percentage of activated macrophages/microglia in the brain than females, as well as increased expression of VLA-4 adhesion molecules in both the brain and spleen \[[@pone.0227481.ref039]\]. However, microglia (MG) from female mice had higher expression of IL-4 and IL-10 receptors and increased production of IL-4, especially after treatment with IL-10 (+) B-cells, which indicated that females had heightened sensitivity of MG to IL-4 and IL-10 as direct B-cell/MG interactions promote M2-MG \[[@pone.0227481.ref040]\]. The incongruent results of immune cell participation were related to stroke stage and age. In our study, the increased DEGs, including interleukins and CXCLs, indicated chronic immune activation of cytokine pathways in males might lead to a protective, instead of damaging, process of neuron regeneration.

Another aspect of female and male IS mechanisms would be cross-talk of inflammation and immune processes between apoptosis pathways. For GO biological process enrichment analysis ([Table 1](#pone.0227481.t001){ref-type="table"}), the male-specific DEGs were involved in regulation of the apoptotic process (GO.0042981), regulation of cell death (GO.0010941), positive regulation of cell death (GO.0010942), and positive regulation of programmed cell death (GO.0043068). NF-kappa B-signalling pathway including BCL2A1, CCL4, CXCL2, ICAM1, IL1B, PTGS2, were significantly enriched in male IS patients ([Fig 5](#pone.0227481.g005){ref-type="fig"}). Male IS presented upregulated BCL2A1 and CXCL2, while female IS presented downregulated BCL2A1 in this study ([Fig 4](#pone.0227481.g004){ref-type="fig"}). The anti-apoptosis protein BCL2 could provide neuron protectiveness via different pathways \[[@pone.0227481.ref041]\]. Therefore, the apoptosis modulation between females and males would be a cause for different outcomes between them. The mitochondrion is a key factor both in acute and chronic stroke damage recovery \[[@pone.0227481.ref042]\]. However, since our dataset is based on human blood samples, there would be insufficiency on this platform to screen metabolic processes which mainly occur in the cytoplasm and mitochondrion. The sample size is also another restriction of this study, even though we hope the significant results could raise more attention, so the sex specific mechanism could lead to the modifications of the current clinical practice.

5. Conclusion {#sec020}
=============

The analysis of sex-specific DEGs from GEO human blood samples showed not only specific but also opposite DEG alterations in females and males such as IL6, in the stroke genome-wide dataset. The inflammatory immune process and anti-apoptosis pathways presented divergent sex-specific alterations in IS. The results provided an overview of sex-specific mechanisms, which delivered further insight into stroke and potential biomarkers that can lead to sex-specific prognosis and treatment strategies in future clinical practice. However, detailed experimental validation through a combination of *in vitro* and *in vivo* testing is still required.

Supporting information {#sec021}
======================
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